The emergence of constitutively active androgen receptor (AR) splice variant AR‐V7 poses a formidable challenge in treating prostate cancer, as it lacks the ligand binding region targeted by androgen‐deprivation therapies such as enzalutamide and abiraterone. This evidence concerns the gene AR and Familial prostate cancer.